Psychedelics

From informed consent in treatment with psychedelics to an anti-fentanyl antibody that may reverse the signs of carfentanil overdose, here are highlights from the week in Psychiatric Times.

In this CME article, learn more about the best practices for engaging patients in the informed consent process for psychedelic treatment and psychedelic-assisted psychotherapy.

From the brain-gut connection to neurocognitive and neuropsychiatric symptoms of long COVID, here are highlights from the week in Psychiatric Times.

A phase 2A trial recently received confirmation to proceed in investigating psilocybin-assisted psychotherapy in the treatment of adult patients with IBS.

Psychiatry: a field of medicine that is constantly evolving.

From research updates on at-home ketamine use to the effects of comorbid depression and anxiety on insomnia treatment, here are highlights from the week in Psychiatric Times.

"If we ignore or do not successfully address these future risks, we may need more than luck to avoid these looming disasters."

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

One psychiatrist recounts his experience with ketamine.

The second coming of psychedelics… what will the outcome be?

From an update on at-home ketamine therapy to the psychopharmacologic treatment of bipolar depression, here are highlights from the week in Psychiatric Times.

The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

Remember to keep the cart behind the horse while practicing medicine.

Selections from the 2022 Psychiatric Times cover features.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

From the unique challenges of treating physician-patients to updates on MDMA and psilocybin research and access, here are highlights from the week in Psychiatric Times.

A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.

The second of a phase 3 study examining MDMA-AT just completed its final participant visit.

A single dose of psilocybin could help patients with treatment-resistant depression, according to a new study.

Classic psychedelic research is rapidly expanding...

Vol. 39, Issue 9 covers the latest in psychedelics research and development in psychiatry.

In a well-blinded study, researchers investigated and directly compared the acute effects of LSD and psilocybin in healthy participants.

How can a robust understanding of the altered-state experience drive the development of therapeutic frameworks that are designed around that experience?

The underlying neural mechanisms identified may help clinicians better understand ketamine response in human patients.

This new study is evaluating how effective psychedelics can be in the treatment of binge eating disorder.

Numinus' Chief Clinical Officer shares resources about the potential use of ketamine in psychiatry.

The first patient has been dosed in the phase 2b dose-optimization trial of a pharmaceutically optimized form of LSD for the treatment of generalized anxiety disorder.

This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."